The Role of Central Neck Lymph Node Dissection in the Management of Papillary Thyroid Cancer

Lawrence A. Shirley1, Natalie B. Jones2 and John E. Phay1*

1Department of Surgery, Division of Surgical Oncology, Ohio State University Medical Center, Columbus, OH, United States, 2Ohio Health, Columbus, OH, United States

Papillary thyroid cancer (PTC) is the most common thyroid malignancy, and cervical nodal metastases are frequent at presentation. The most common site for nodal metastases from PTC is the central compartment of the ipsilateral neck in the paratracheal and pretracheal regions. The decision to resect these lymph nodes at the time of thyroidectomy often depends on if nodes with suspected malignancy can be identified preoperatively. If nodal spread to the central neck nodes is known, then the consensus is to remove all nodes in this area. However, there remains significant controversy regarding the utility of removing central neck lymph nodes for prophylactic reasons. Herein, we review the potential utility of central neck lymph node dissection as well as the risks of performing this procedure. As well, we review the potential of molecular testing to stratify patients who would most benefit from this procedure. We advocate a selective approach in which patients undergo clinical neck examination coupled with ultrasound to detect any concerning lymph nodes that warrant additional evaluation with either fine needle aspiration or excisional biopsy in the operating room. In lieu of clinical lymphadenopathy, we suggest the use of patient and disease characteristics as identified by multiple groups, such as the American Thyroid Association and European Society of Endocrine Surgeons, which include extremes of ages, large primary tumor size, and male gender, when deciding to perform central neck lymph node dissection. Patients should be educated on the potential long-term risks versus the lack of known long-term benefits.

Keywords: papillary thyroid cancer, central neck dissection, lymph nodes, prophylactic surgery, surgical complications

INTRODUCTION

Papillary thyroid cancer (PTC) makes up approximately 74–85% of all forms of thyroid cancer. The incidence of PTC has been rising in the United States over the past 30 years from 3.6 per 100,000 in 1973 to 9.1 per 100,000 (females) and 2.9 per 100,000 (males) in 2011 (1). Most of this increase in PTC can be attributed to the incidental finding of small tumors (<1 cm) as a result of the increased use of ultrasound and computed tomography scans for a variety of other conditions. PTC is more common in women, whereas in men it tends to be more aggressive and occurs at a later age. Patients with PTC tend to have an excellent prognosis with an overall 10-year survival of 93% (2). Approximately 1,500 patients die per year of PTC and the patients who do succumb to the disease frequently develop respiratory failure due to extensive pulmonary metastases (3).
Lymph node metastases are a common occurrence in PTC, despite excellent long-term survival. Studies have demonstrated that micrometastases can be found in the central cervical lymph nodes in 40–60% of cases (4, 5). Preoperatively, patients should undergo a clinical neck examination in combination with a high resolution neck ultrasound in order to detect any concerning lymph nodes that would warrant further investigation. Unfortunately, lymph nodes in the central neck compartment are more difficult to image via ultrasound when compared to the lateral neck due to their proximity to the thyroid gland and air-filled trachea (5, 6). Ahn et al. found that the sensitivity of detection of lateral compartment lymph nodes was 94%, compared to 53–55% in the central neck (7). Concerning lymph nodes visualized on ultrasound should then be sampled using fine needle aspiration (FNA) if it will change the extent of the operation. Cytologic analysis should be performed, and thyroglobulin (Tg) washings may be done, although Tg washings may be prone to a high false-positive rate if the thyroid gland is still present. A finding of malignancy by FNA would lead to the removal of lymph nodes within the central compartment of the neck, so-called therapeutic central neck lymph node dissection (CLND) at the time of total thyroidectomy. A lymph node found to be highly suspicious by ultrasound criteria, which typically includes a cystic component or hyperechoic punctations, does not always need confirmation by FNA especially when characterized by an experienced ultrasonographer (8). Other less-specific ultrasound characteristics, including a round shaped and loss of a hilum, may raise enough suspicion that FNA may be beneficial. If, at the time of thyroidectomy, firm, enlarged, or discolored lymph nodes are identified, the decision can be made to complete a CLND to clear all potential lymph node metastases. Patients with coexisting chronic lymphocytic thyroiditis often have multiple enlarged benign inflamed lymph nodes, making the decision to perform a CLND difficult. Frozen section analysis of these nodes may aid in the decision about completing a CLND. However, when preoperative or intraoperative investigations do not demonstrate evidence of lymph node spread, the surgeon must then make the difficult decision of performing a CLND for prophylactic reasons.

**DEFINITION OF A CENTRAL NECK LYMPH NODE DISSECTION**

The central neck compartment includes Level VI, the anatomic area bounded by the hyoid bone superiorly, the sternal notch inferiorly, and the medial borders of the carotid sheaths laterally (Figure 1). The structures found in this compartment are the esophagus, recurrent laryngeal nerves, trachea, parathyroid glands, thymus, and thyroid gland. The lymph nodes included in this compartment are the paratracheal, prelaryngeal, and pretracheal nodes. Lymph nodes found from the level of the sternal notch to the level of the innominate vein are described as Level VII lymph nodes, some or all of which are often removed during CLND (9, 10). Within the central compartment, lymph nodes tend to be more abundant superior to the isthmus (also called Delphian nodes) and inferior to the lobes bilaterally with fewer located above the superior poles of the thyroid. An ipsilateral central neck dissection involves removal of nodes on the same side as the thyroid cancer, whereas a bilateral CLND would include resection of all lymph nodes found in this central

---

**FIGURE 1** | The anatomic borders of Level VI of the central neck (hyoid bone, carotid arteries, and sternal notch), where lymph nodes are resected when completing a bilateral central neck dissection. © Ohio State University.
compartments. As the inferior thyroid artery commonly supplies both parathyroid glands, care must be taken not to injure this vessel during dissection. The recurrent laryngeal nerves should be directly visualized throughout the nodal dissection in order to avoid injury.

BENEFITS AND RISKS OF PROPHYLACTIC CENTRAL NECK LYMPH NODE DISSECTION

Unlike in virtually all other solid malignancies, initial studies on the prognosis of differentiated thyroid cancer failed to show prognostic significance of regional lymph node involvement. This was reflected in that traditional staging systems, including metastases, age, completeness of resection, invasion, size and age, metastases, extent of primary cancer, size, does not include lymph node status in determining prognosis. However, with the use of a larger database, Mazzaferrri and Jihang demonstrated that patients with lymph node metastases did, in fact, have a worse prognosis (11). Subsequent large-scale studies have generally corroborated these findings (12, 13), especially, in older patients. This is reflected in the current American Joint Committee on Cancer staging system, where lymph node involvement upstages patients older than 45 years from stage II to stage III. As it has taken large databases to show small but usually significant differences in survival with nodal disease, there remains a lack of good evidence that removing involved nodes improves survival. As prophylactic lymph node dissection by definition removes microscopic disease, it is generally accepted that this procedure does not change overall prognosis but may affect recurrence rates (14). However, convincingly demonstrating a recurrence difference may be challenging. The American Thyroid Association (ATA) assessed the feasibility of performing a randomized controlled trial to evaluate the benefit of prophylactic CLND and estimated that it would take over 5,000 enrollees and over $15 Million to perform (15). In general, the goals of prophylactic CLND are not to improve survival, but to potentially avoid reoperative high-risk surgery from recurrences, minimizing biochemical evidence of disease, and simplifying follow-up.

The decision to perform therapeutic CLND is dependent on information gained through clinical examination, preoperative ultrasound, and intraoperative assessment. However, these tools have been shown to be unreliable in determining the presence of microscopic lymph node metastases (16, 17). With this in mind, along with the known very high prevalence of central neck lymph node metastases, several groups advocate routine prophylactic CLND. Prophylactic CLND potentially decreases recurrent central neck disease. Hall et al. reported no central neck lymph node recurrences in 266 patients undergoing routine CLND (18). The potential oncologic benefit of routine CLND has been supported through studies showing that performing CLND was associated with decreased Tg levels postoperatively (19–21). Lower Tg levels would potentially increase the sensitivity for using Tg for long-term surveillance. As well, having undetectable Tg levels decreases patient's mental anguish and could decrease surveillance frequency and cost. Lower Tg levels after CLND implies that removing central neck lymph nodes routinely reduces the burden of disease. A recent meta-analysis of 2,318 patients saw a trend toward lower recurrence rate when prophylactic CLND was performed, whereas this did not reach statistical significance (22). As previously mentioned, only an extremely large randomized control trial may definitively answer this question, but is unlikely to be performed.

Another potential benefit of prophylactic CLND has been to more accurately stage patients, which can clearly affect RAI treatment. In two retrospective studies, approximately one-third of patients older than 45 years were upstaged to stage III disease (23, 24). However, in a recently published randomized control trial (25), where 181 patients were randomized to total thyroidectomy plus prophylactic CLND versus total thyroidectomy alone, clinically relevant up-staging occurred in only one patient. Still, in patients with CLND, there was a reduced need to perform repeated I-131 treatments. Prophylactic CLND resulting in different radioactive I-131 ablation treatments has also been demonstrated in other retrospective reviews (26, 27). With the current ATA guidelines recommending assessing the size and number of lymph nodes involved before deciding on RAI treatment, prophylactic CLND may play an even larger role in determining RAI use. A prophylactic CLND that demonstrates a lack of lymph node metastasis would strengthen the case not to use RAI treatment in a low-risk patient. Thus, the performance of CLND can potentially have a significant impact on further treatment regimens, although the degree of impact remains a matter of debate.

CLND has several associated risks, including increased risk of hypoparathyroidism and recurrent laryngeal nerve injury over thyroidectomy alone (28). A meta-analysis of over 3,000 patients found that temporary hypocalcemia and temporary vocal cord paralysis were more common in patients undergoing CLND versus thyroidectomy alone but that there were no differences in permanent hypocalcemia or vocal cord injury (23). An Italian series of 1,087 patients assessed differences in complications with thyroidectomy plus bilateral CLND compared to ipsilateral CLND or no dissection. The bilateral CLND group had a significantly higher rate of permanent hypoparathyroidism compared to the other two groups (bilateral 16%, ipsilateral 7%, and no CLND 6.3%). There were no significant differences in the rates of permanent recurrent nerve injury although the bilateral group trended toward an increased injury rate (bilateral 2.3%, ipsilateral 0.5%, and no CLND 1%). They concluded that a contralateral neck dissection should only be performed in the presence of ipsilateral lymph nodes metastases on frozen section (24).

When assessing risks of CLND, it is important to consider that it is often more difficult to reoperate on patients with recurrent disease. In a study of reoperation for recurrent differentiated thyroid cancer, permanent vocal cord paralysis occurred in 18% of patients, mostly due to intentional nerve resection due to tumor invasion. In addition, hypoparathyroidism was also frequent in reoperative cases (29). A study by Shen et al. reviewed 295 CLNDs, 189 initial and 106 reoperations, comparing complications between the two surgery types (30). They found transient hypocalcemia was significantly higher in the initial CLND group (41.8 versus 23.6%), but there were no significant differences in permanent hypocalcemia, or transient or permanent hoarseness.
Thus, they concluded that observing non-enlarged lymph nodes did not result in increased complications when reoperation was required. Recent retrospective studies have shown that observation of selected patients with low-risk PTC had low rates of recurrence, from 0.4 to 1.8% (31, 32), such that a small minority of patients will require a reoperation. As such, potential need for later reoperation should not, in and of itself, dictate the need for prophylactic CLND.

**LATERAL COMPARTMENT DISEASE WITHOUT CENTRAL INVOLVEMENT**

Generally, the most common pattern of lymph node spread is first to the central lymph node compartment (Level VI) followed by the lateral neck (Levels II–IV). In a retrospective review of patients who presented with clinically positive neck lymph nodes, 95% of patients had Level VI lymph node involvement, while the lateral neck was involved between 54 and 68% of the time (33). The pattern of spread suggests a typical step-wise progression from central to lateral neck compartments. As such, several groups propose that prophylactic removal of central neck nodes is beneficial in preventing local recurrence and further metastatic spread to regional lymph nodes. Nonetheless, there is the potential for “skip metastases” where patients have spread to lateral cervical nodes, without disease in the central neck. Reports of such phenomena have ranged from 6.8 to 37.5% for node-positive PTC (34–36). Studies have looked at predictors of “skip metastases,” showing higher likelihood in tumor in either the upper poles or lateral aspects of the thyroid lobe, as these tumors may be in closer proximity to nodes in the jugular chain than the more inferior central nodes. Although this brings into question the potential benefit of preventing further spread by clearing central neck micrometastases, it is important to note that “skip metastases” occur in the minority of patients. Still, when clinically positive lateral cervical lymph nodes are diagnosed preoperatively, standard-of-care remains to routinely perform a CLND at the time of resection. In addition, further studies have shown that if lymph node sampling is performed, a formal dissection should be performed rather than selective “berry-picking” of abnormal lymph nodes (37, 38).

**PATIENT SELECTION FOR PROPHYLACTIC CENTRAL NECK LYMPH NODE DISSECTION**

Although there is strong consensus to perform CLND for therapeutic purposes, there is currently considerable controversy among endocrine surgeons regarding which patients should undergo prophylactic CLND for PTC. The 2009 ATA consensus statement recommends therapeutic CLND for any patients with clinically positive nodes and prophylactic CLND for patients with T3 and T4 primary tumors without evidence of nodal metastases, or with known lateral lymph node metastasis (39, 40). These general recommendations remained intact in the 2015 update, with the addition that prophylactic CLND may be performed if the information gained will guide further steps in therapy (41). As well, the 2015 guidelines add a statement that it is appropriate to not perform a prophylactic CLND for T1 or T2 tumors.

The controversies surrounding performance of a prophylactic CLND can be reflected in the varying recommendations from other national and international consensus groups as seen in Table 1. The National Comprehensive Cancer Network expert panel gives prophylactic CLND a Category 2B recommendation, stating that performance for patients with T3 or T4 tumors could be considered, but must be weighed against the increased risk of hypoparathyroidism and nerve injury (42). The British Thyroid Association, in their recommendations released in 2014, states that the benefit for prophylactic CLND in high-risk patients is unclear, and as such, they state that decision-making should be personalized. They do state that bilateral CLND has a benefit over ipsilateral CLND (43). The European Society of Endocrine Surgeons state that prophylactic CLND should be considered in those with high-risk features, including T3-4 tumors, age <15 or >45, male gender, bilateral or multifocal disease, or known lateral neck lymph node metastases (44). As well, this group emphasizes the importance of prophylactic CLND being done by surgeons in specialized centers. In contrast to these organizations, the Japanese Society of Thyroid Surgeons/Japanese Association of Endocrine Surgeons recommends routine performance of prophylactic CLND, based on increased risk of complications if surgery is needed for lymph node recurrence (45).

High-risk features of the primary tumor might help predict nodal positivity; however, many of these features are unknown prior to surgery. Some factors that can be assessed preoperatively and are associated with aggressive disease include extremes of age, male gender, large primary tumor size, or bilateral disease. Pathologic features that are predictive of aggressive variants of PTC include tumor subtypes such as tall cell, columnar cell, Hurthle cell, diffuse sclerosis, and insular variants, as well as

| Consensus group | Year | Recommendations for prophylactic CLND for PTC |
|-----------------|------|---------------------------------------------|
| American Thyroid Association (41) | 2015 | Consider for T3/T4 tumors or clinically involved lateral neck nodes or if the information will impact further steps in therapy |
| National Comprehensive Cancer Network (42) | 2016 | Consider for patients with T3/T4 tumors, but must weigh against the risk of hypoparathyroidism and nerve injury |
| British Thyroid Association (43) | 2014 | Benefit is unclear in high-risk patient, such that decision-making should be personalized. Bilateral CLND should be performed over ipsilateral CLND |
| European Society of Endocrine Surgeons (44) | 2014 | To be considered for patients with high-risk features, including T3/T4 tumors, extremes of age, male gender, bilateral/multifocal disease, clinically positive lateral lymph nodes. To be performed in specialized centers |
| Japanese Society of Thyroid Surgeons/Japanese Association of Endocrine Surgeons (45) | 2011 | To be performed routinely |
the presence of vascular invasion, extrathyroidal extension, and poorly differentiated tumors (46). Roh et al. prospectively examined 184 patients with unilateral PTC and clinically node negative disease by physical exam and ultrasound. All patients underwent total thyroidectomy and prophylactic CLND. The overall rates of lymph node metastasis were 42.9% to the ipsilateral central neck and 9.8% to the contralateral central neck compartments. In their multivariate analysis, tumor size >1 cm, extrathyroidal extension, and age <45 years were predictive of ipsilateral metastases. In addition, ipsilateral positive lymph nodes were most predictive of contralateral central neck positive lymph nodes. Of note, the rate of occult contralateral thyroid papillary microcarcinoma was 16.7% (5). In their review of 273 patients treated at the University of Chicago, Siddiqui et al. (47) found that age <45, multifocality, and extrathyroidal extension increased risk of central neck lymph node metastasis. They further systematically evaluated 10 previous studies that assessed risk factors for central neck lymph node metastases, including age, sex, tumor size, multifocality, bilaterality, thyroiditis, and extrathyroidal extension. There were no factors that were consistently associated with metastasis, yet the most common factors were large tumor size (eight studies) and presence of extrathyroidal extension (eight studies).

As in other cancer types, it has been proposed that sentinel lymph node biopsy could be performed to find patients with occult PTC lymph node metastases not identified by traditional preoperative and intraoperative methods. In these cases, if the sentinel node is positive, the patient would undergo a therapeutic CLND, and if the node is negative, the patient could be spared the increased morbidity of an unnecessary CLND. Several groups have shown promising initial results with traditional methods including methylene blue or isosulfan blue dye (48–50) and radioisotope injections, although many of these studies did not differentiate between central and lateral lymph nodes. These studies, as well as more recent studies assessing nanoparticles (51) and single-photon emission computed tomography and computed tomography (SPECT/CT) (52) show feasibility of technique, while many admit to high false negative rates. There is no direct evidence that sentinel lymph node biopsy has long-term benefits on patient outcomes (53). However, future studies of these more novel technologies may improve our ability to reliably select which patients should undergo CLND.

A greater understanding of molecular signaling pathways has the potential to better stratify patients who could benefit from prophylactic CLND. It is well known that mutations in the MAPK pathway are frequent driver mutations for PTC. One of the strongest activators of the MAPK pathway is the BRAF gene, found on chromosome 7. The most common genetic alteration found in PTC is the BRAFV600E mutation, with a reported frequency of 70–80% (53). The presence of the BRAFV600E mutation has shown to have significantly shorter progression-free survival (61), clearly suggesting more aggressive tumor biology. As it stands currently in the published literature, there is no definite molecular marker, even BRAFV600E, which can definitely predict central neck lymph node metastases. As such, we would not recommend an established molecular test to guide operative decision-making. Nonetheless, as more factors are uncovered and their interrelationships elucidated, preoperative molecular testing may one day allow for stratifying patients who are candidates for prophylactic CLND. This provides a clear avenue of translating basic science discoveries into improvements in clinical care.

At our institution, there are no hard patient characteristics that define the use of prophylactic CLND, as different surgeons have different thresholds as to when it is appropriate. We always perform a thorough neck ultrasound performed by either the surgeon themselves or a referring endocrinologist skilled in ultrasound. Detailed attention is given to the characteristics of the primary tumor, such as local invasion, as well as the degree of suspicion in lymph nodes in the central and lateral cervical compartments with potential FNA of nodes as previously discussed. Certain characteristics about the primary tumor favor the use of prophylactic CLND. Extrathyroidal extension either seen on preoperative ultrasound or discovered intraoperatively warrants this procedure. Multifocal disease, if known preoperatively, favors it use as well. If lymph nodes are found to be slightly enlarged either on ultrasound or intraoperatively, a prophylactic CLND is more likely, even if the enlarged nodes have a benign appearance. Size of the primary tumor also impacts the use of prophylactic surgery. CLND is virtually never done for cancers <1 cm, but usually done for tumors >3 cm. A prophylactic CLND is more likely to be done on male patients and older patients given the worse prognosis with lymph node involvement. If there is concern about recurrent laryngeal nerve function at the time of surgery, then a prophylactic CLND is less likely to be done. In the future, we would hope that more precise molecular profiling could be performed on these patients preoperatively in order to more reliably assess the patients who would best benefit from prophylactic CLND.

**CONCLUSION**

Papillary thyroid cancer is the most common thyroid malignancy, and metastatic spread involving lymph nodes of the central neck is common. The role of prophylactic CLND for PTC continues to be controversial. With the available evidence, we advocate a
selective approach to performing prophylactic CLND. Per many international consensus panels, patients with larger tumors and unfavorable patient characteristics are more likely to benefit from prophylactic CLND, making these patients likely candidates for this procedure. However, such patients should also be aware of the potential for increased risks of hypoparathyroidism and recurrent nerve injury after a CLND over thyroidectomy, as well as questionable long-term benefits. Although recently tested molecular markers have contradictory findings, discovery of novel mutations and other biomarkers could potentially be used to better predict preoperatively that patients should undergo a CLND at the time of thyroidectomy in a more personalized manner.

**AUTHOR CONTRIBUTIONS**

JP provided the idea and critical review. NJ contributed writing parts of the initial text. LS wrote the completed text.

**REFERENCES**

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin (2011) 61(2):69–90. doi:10.3322/caac.20070
2. Hundahl SA, Fleming ID, Fremgen AM, Menck HR, et al. A national cancer data base report on 53,856 cases of thyroid cancer treated in the U.S. 1985–1995. *Cancer* (1998) 839(12):2638–48. doi:10.1002/(SICI)1097-0142(19981215)83:12<2638::AID-CNCR31>3.0.CO;2-1
3. Kitamura Y, Shizumi K, Nagahama M, Sugino K, Ozaki O, Mimura T, et al. Immediate cures of death in thyroid carcinoma: clinicopathological analysis of 161 fatal cases. *J Clin Endocrinol Metab* (1999) 84(11):4045–94. doi:10.1210/jcem.84.11.6115
4. Pereira JA, Jimeno J, Miquel J, Iglesias M, Munné A, Sancho JJ, et al. Nodal yield, morbidity, and recurrence after central neck dissection for papillary thyroid carcinoma. *Surgery* (2005) 138(6):1095–101. doi:10.1016/j.surg.2005.09.013
5. Roh J-L, Kim J-M, Park C. Central lymph node metastasis of unilateral papillary thyroid carcinoma: patterns and factors predictive of nodal metastasis, morbidity, and recurrence. *Ann Surg Oncol* (2011) 18:2245–50. doi:10.1245/s10434-011-1600-z
6. Kouvarakai MA, Shaprio SE, Fornage BD, Edeiken-Monroe BS, Sherman SI, Vassilopoulou-Sellin R, et al. Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer. *Surgery* (2003) 134(6):946–54. doi:10.1016/S0039-6060(03)00424-0
7. Ahn JE, Lee JH, Yi JS, Shong YK, Hong SJ, Lee DH, et al. Diagnostic accuracy of CT and ultrasonography for evaluating metastatic cervical lymph nodes in patients with thyroid cancer. *World J Surg* (2008) 32(7):1552–8. doi:10.1007/s00268-008-9588-7
8. Leboullieux S, Girard E, Rose M, Traverg JP, Sabbah N, Cailou B, et al. Ultrasound criteria of malignancy for cervical lymph nodes in patients followed up for differentiated thyroid cancer. *J Clin Endocrinol Metab* (2007) 92(9):3590–9. doi:10.1210/jc.2007-0444
9. Friedmann M, Kanwar K, Maley A. Central neck dissection. *Operative Tech Otolaryngol* (2011) 22:169–72. doi:10.1067/mto.2011.04.001
10. American Thyroid Association. Surgery Working Group, American Association of Endocrine Surgeons, American Academy of Otolaryngology-Head and Neck Surgery, American Head and Neck Society, Carty SE, Cooper DS, et al. Consensus statement on the terminology and classification of central neck dissection for thyroid cancer. *Thyroid* (2009) 19(10):1153–8. doi:10.1089/thy.2009.0159
11. Mazzaferrin EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. *Am J Med* (1994) 97(5):418–28. doi:10.1016/0002-9343(94)90321-2
12. Podnos YD, Smith D, Wageman LD, Ellenhorn JD. The implication of lymph node metastasis on survival in patients with well-differentiated thyroid cancer. *Am Surg* (2005) 71(9):731–4.
13. Zaydfudim V, Feurer ID, Griffin MR, Phay JE. The impact of lymph node involvement on survival in patients with papillary and follicular thyroid carcinoma. *Surgery* (2008) 144(6):1070–7. doi:10.1016/j.surg.2008.08.034
14. Mazzaferrin EL. A vision for the surgical management of papillary thyroid carcinoma: extensive lymph node compartmental dissections and selective use of radioiodine. *J Clin Endocrinol Metab* (2009) 94(4):1086–8. doi:10.1210/jc.2009-0298
15. Cuny T, Carty SE, Ciarellegio MM, Cooper DS, Doherty GM, Kim JT, et al. American Thyroid Association design and feasibility of a prospective randomized controlled trial of prophylactic central lymph node dissection for papillary thyroid carcinoma. *Thyroid* (2012) 22(3):237–44. doi:10.1089/thy.2011.0317
16. Moreno MA, Edeiken-Monroe BS, Siegel ER, Sherman SI, Claman GL. In papillary thyroid cancer, prophylactic central neck ultrasound detects only macroscopic surgical disease, but negative findings predict excellent long-term regional control and survival. *Thyroid* (2012) 22:347–55. doi:10.1089/thy.2011.0211
17. Hwang HS, Orloff LA. Efficacy of preoperative neck ultrasound in the detection of cervical lymph node metastasis from thyroid cancer. *Laryngoscope* (2011) 121:487–91. doi:10.1016/j.lary.2011.02.004
18. Hall CM, Snyder SK, Maldonado YM, Lairmore TC. Routine central lymph node dissection with total thyroidectomy for papillary thyroid cancer potentially minimizes level VI recurrence. *Surgery* (2016) 160(4):1049–58. doi:10.1016/j.surg.2016.06.042
19. Popadich A, Levin O, Lee JC, Smooke-Praw S, Ro K, Fazel M, et al. A multicenter cohort study of total thyroidectomy and routine central lymph node dissection for cN0 papillary thyroid cancer. *Surgery* (2011) 150:1048–57. doi:10.1016/j.surg.2011.09.003
20. So YK, Seo MY, Son YJ. Prophylactic central lymph node dissection for clinically negative papillary thyroid microcarcinoma: influence on serum thyroglobulin level, recurrence rate, and postoperative complications. *Surgery* (2012) 151:192–8. doi:10.1016/j.surg.2011.02.004
21. Sywak M, Cornford L, Roach P, Stalberg P, Sidhu S, Delbridge L. Routine ipsilateral level VI lymphadenectomy reduces postoperative thyroglobulin levels in papillary thyroid cancer. *Surgery* (2006) 140(6):1000–5. doi:10.1016/j.surg.2006.08.001
22. Wang TS, Cheung K, Farrokhyar F, Roman SA, Sosa JA. A meta-analysis of the effect of prophylactic central compartment neck dissection on locoregional recurrence rates in patients with papillary thyroid cancer. *Ann Surg Oncol* (2013) 20(11):3477–83. doi:10.1245/s10434-013-3125-0
23. Shan CX, Zhang W, Jiang DZ, Zheng XM, Liu S, Qu M. Routine central neck dissection in differentiated thyroid carcinoma: a systematic review and meta-analysis. *Laryngoscope* (2012) 122(4):797–804. doi:10.1002/lary.21262
24. Giordano D, Valcari R, Thompson GB, Pedroni C, Renna L, Gradeni P, et al. Complications of central neck dissection in patients with papillary thyroid carcinoma: results of a study on 1087 patients and review of literature. *Thyroid* (2012) 22(9):911–7. doi:10.1089/thy.2012.0011
25. Viola D, Materazzi G, Valerio L, Molinaro E, Agate L, Fiviana P, et al. Prophylactic central compartment lymph node dissection in papillary thyroid carcinoma: clinical implications derived from the first prospective randomized controlled single institution study. *J Clin Endocrinol Metab* (2015) 100(4):1316–24. doi:10.1210/jc.2014-3825
26. Bonnet S, Hartl D, Leboullieux S, Baudin E, Al Ghuzlan A, et al. Prophylactic lymph node dissection for papillary thyroid cancer less than 2 cm: implications for radioiodine treatment. *J Clin Endocrinol Metab* (2009) 94(4):1162–7. doi:10.1210/jc.2008-1931
27. Hughes DT, White ML, Miller BS, Gauger PG, Burney RE, Doherty GM. Influence of prophylactic central lymph node dissection in postoperative thyroglobulin levels and radiodine treatment in papillary thyroid cancer. *Surgery* (2010) 148:1100–6. doi:10.1016/j.surg.2010.09.019
28. Ywata de Carvalho A, Chulam TC, Kowalski LP. Long-term results of observation vs prophylactic selective level VI neck dissection for papillary thyroid carcinoma at a cancer center. *JAMA Otolaryngol Head Neck Surg* (2015) 141:599–606. doi:10.1001/jamaoto.2015.0786
29. Roh JL, Kim JM, Park CL. Central compartment reoperation for recurrent/persistent differentiated thyroid cancer: patterns of recurrence, morbidity, and complications.
32. Nixon IJ, Ganly I, Patel SG, Morris LG, Thomas D, et al. Observation of clinically negative central compartment lymph nodes in papillary thyroid carcinoma. J Exp Clin Cancer Res (2017) 36(3):87–91. doi:10.1007/s10434-016-2339-1

33. Scheumann GF, Gimm O, Wegener G, Hundeshagen H, Drahle H. Prognostic significance and surgical management of locoregional lymph node metastases in papillary thyroid cancer. World J Surg (1994) 18(4):559–67. doi:10.1007/BF00357365

34. Musacchio MJ, Kim AW, Vujingco JD, Prinz RA. Greater local recurrence occurs with “berry-picking” than neck dissection in thyroid cancer. Am Surg (2003) 69(5):191–6.

35. Shimosato Y, Shin SC, Lim YS, Lee JC, Wang SG, Son SM, et al. Tumor location-dependent skip lateral cervical lymph node metastasis in papillary thyroid cancer. Head Neck (2014) 36(6):887–91. doi:10.1002/hed.23391

36. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. American Thyroid Association (ATA) guidelines taskforce on thyroid nodules and differentiated thyroid cancer: updated American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. (2009) 19(11):1167–214. doi:10.1089/thy.2009.0110

37. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task force on thyroid nodules and differentiated thyroid cancer. Thyroid (2016) 26(1):1–33. doi:10.1089/thy.2015.0020

38. National Comprehensive Cancer Network. Thyroid Carcinoma (Version 1,2016). (2016). Available from: https://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf

39. Perros P, Boelaert K, Colley S, Evans C, Evans RM, Gerrard GE, et al. Guidelines for the management of thyroid cancer. Clin Endocrinol (2011) 84(Suppl 1):1–122. doi:10.1111/j.1365-2265.12151

40. Sancho J, Lennard TW, Paunovic I, Trippone E, Sitges-Serra A. Prophylactic central neck dissection in papillary thyroid cancer: a consensus report of the European Society of Endocrine Surgeons (ESES). Langenbecks Arch Surg (2014) 399:155–63. doi:10.1007/s00423-013-1152-8

41. Takami H, Ito Y, Okamoto T, Yoshida A. Therapeutic strategy for differentiated thyroid carcinoma in Japan based on a newly established guideline managed by Japanese Society of Thyroid Surgeons and Japanese Association of Endocrine Surgeons. World J Surg (2011) 35:111–21. doi:10.1007/s00268-010-0832-6

42. Mazzaferrri EL, Kloos RT. Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab (2001) 86(4):1447–63. doi:10.1210/jcem.86.4.7407

43. Siddiqui S, White MG, Antic T, Grogan RH, Angelos P, Kaplan EL, et al. Clinical and pathologic predictors of lymph node metastasis and recurrence in papillary thyroid microcarcinoma. Thyroid (2016) 26(7):807–15. doi:10.1089/thy.2015.0429

44. Dzodic R, Markovic I, Inic M, Iocic N, Djuricic I, Zegarac M, et al. Sentinel lymph node biopsy may be used to support the decision to perform modified radical neck dissection in differentiated thyroid carcinoma. World J Surg (2006) 30:841–6. doi:10.1002/wj.2989-0

45. Takami H, Ito Y, Okamoto T, Yoshida A. Therapeutic strategy for differentiated thyroid carcinoma. World J Surg (2016) 40(10):2725–32. doi:10.1007/s00268-016-7984-x

46. Mazzaferri EL, Kloos RT. Greater local recurrence is associated with tumor aggressiveness in papillary thyroid cancer. J Clin Oncol (2011) 29:1214–21. doi:10.1200/JCO.2010.32.0610

47. Cunningham DK, Yao KA, Turner RR, Singer FR, Van Herle AR, Giuliano AE. Sentinel lymph node biopsy for papillary thyroid cancer: 12 years of experience at a single institution. Ann Surg Oncol (2010) 17:2970–5. doi:10.1245/s10434-010-1141-x

48. Ji YB, Lee KJ, Park YS, Hong SM, Paik SS, Tae K. Clinical efficacy of sentinel lymph node biopsy using methylene blue dye in clinically node-negative papillary thyroid carcinoma. Ann Surg Oncol (2012) 19(6):1686–73. doi:10.1245/s10434-011-2109-1

49. Yan X, Zeng R, Ma Z, Chen C, Chen E, Zhang X, et al. The utility of sentinel lymph node biopsy in papillary thyroid carcinoma with occult lymph nodes. PLoS One (2015) 10(6):e0129304. doi:10.1371/journal.pone.0129304

50. Ji YB, Lee KJ, Park YS, Hong SM, Paik SS, Tae K. Clinical efficacy of sentinel lymph node biopsy using methylene blue dye in clinically node-negative papillary thyroid carcinoma. World J Surg (2016) 40(10):2725–32. doi:10.1007/s00268-016-7984-x

51. Cabrera RN, Chone CT, Zantut-Wittmann D, Matos P, Ferreira DM, Pereira PS, et al. Value of sentinel lymph node biopsy in papillary thyroid cancer: initial results of a prospective trial. Eur Arch Otorhinolaryngol (2015) 272(4):971–9. doi:10.1007/s00410-015-3018-2

52. Cabrera RN, Chone CT, Zantut-Wittmann D, Matos P, Ferreira DM, Pereira PS, et al. Value of sentinel lymph node biopsy in papillary thyroid cancer: initial results of a prospective trial. Eur Arch Otorhinolaryngol (2015) 272(4):971–9. doi:10.1007/s00410-015-3018-2

53. Roh JL, Koch WM. Role of sentinel lymph node biopsy in thyroid cancer. Expert Rev Anticancer Ther (2010) 10(9):1429–37. doi:10.1586/era.10.111

54. Caronia LM, Phay JE, Shah MH. Role of BRAF in thyroid oncogenesis. Clin Cancer Res (2011) 17(24):7511–7. doi:10.1158/1078-0432.CCR-11-1155

55. Kim SJ, Lee KE, Myong JP, Park JH, Jeon YK, Min HS, et al. BRAF V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer. World J Surg (2012) 36:310–7. doi:10.1007/s00268-011-1383-1

56. Tufano RP, Bishop J, Wu G. Reoperative central compartment dissection for patients with recurrent/persistent papillary thyroid cancer: efficacy, safety, and association of the BRAF mutation. Laryngoscope (2012) 122:1634–40. doi:10.1002/lary.23371

57. Xing M, Tufano RP, Tufaro AP, Basarisa S, Ewertz M, Rosenbaum E, et al. Detection of BRAF mutation on fine needle aspiration biopsy specimens: a new diagnostic tool for papillary thyroid cancer. J Clin Endocrinol Metab (2004) 89(6):2867–72. doi:10.1210/jc.2003-032050

58. Howell GM, Nikiforova MN, Carty SE, Armstrong MJ, Hodak SP, Stang MT, et al. BRAF V600E mutation independently predicts central compartment lymph node metastasis in patients with papillary thyroid cancer. Ann Surg Oncol (2013) 20(1):47–52. doi:10.1245/s10434-012-2611-0

59. Han PA, Kim HS, Cho S, Fazeli R, Najafian A, Khawaja H, et al. Association of BRAF V600E mutation and microRNA expression with central lymph node metastases in papillary thyroid cancer: a prospective study from four endocrine surgery centers. Thyroid (2016) 26(4):532–42. doi:10.1089/thy.2015.0378

60. Kim SK, Woo JW, Lee JH, Park I, Choe JH, Kim JH, et al. Role of BRAF V600E mutation as an indicator of the extent of thyroidectomy and lymph node dissection in conventional papillary thyroid carcinoma. Surgery (2015) 158(6):1500–11. doi:10.1016/j.surg.2015.05.016

61. Xing M, Liu R, Liu X, Murugan AK, Zhu G, Zeiger MA, et al. BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. J Clin Oncol (2014) 32(25):2718–28. doi:10.1200/JCO.2014.55.5094

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2017 Shirley, Jones and Phay. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.